This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
by Zacks Equity Research
STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.
Perrigo to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
PRGO eyes Q2 results, which are likely to show sales of $1.08 billion, as investors await updates on its Kairos deal and macro pressures.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Tempus AI Taps Growing ICI Market With New xM Assay
by Sridatri Sarkar
TEM launches xM, a liquid biopsy assay to monitor real-time response to ICI therapy in advanced solid tumors.
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
Henry Schein to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
HSIC eyes modest Q2 gains, with dental, medical and specialty segments showing signs of steady momentum.
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
KROS vs. EXAS: Which Stock Is the Better Value Option?
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
by Moumi Mondal
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
by Zacks Equity Research
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tempus AI Raises 2025 Financial Outlook: What's Backing It?
by Sridatri Sarkar
TEM lifts its 2025 revenue and EBITDA outlook on strong Q1 results, key partnerships and testing expansion.
QGEN or EXAS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
QGEN vs. EXAS: Which Stock Is the Better Value Option?
What Makes Exact Sciences (EXAS) a New Buy Stock
by Zacks Equity Research
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.